journal
https://read.qxmd.com/read/38619488/the-impact-of-race-and-ethnicity-on-diffuse-large-b-cell-lymphoma-outcomes-within-the-veterans-health-administration-vha
#1
JOURNAL ARTICLE
Andrew Ta, Supreet Kaur, Michael Mader, Kathleen Franklin, Madison Williams, Ryan Williams, Jean-Pierre Blaize, Amna Naqvi, Snegha Ananth, Michael Song, Brian Oliver Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Phillip Nazarewicz, Manuel Espinoza-Gutarra, Kana Tai Lucero, Jennifer Whitehead, Alaq Al-Abayechi, Lauren Boyle, Sophia Lee, Gabriel Roman Souza, Esteban Toro Velez, Ian Mines, Zohra Nooruddin
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly male (97%) and white (75%). Median age of diagnosis for Black patients was 63 years vs 69 years for the entire cohort ( p  < 0.001). However, patients in each race/ethnicity subgroup presented with similar rates of stage I/II and III/IV disease, IPI score, cell of origin and HIT status...
April 15, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38619476/b-cell-receptor-signaling-proteins-as-biomarkers-for-progression-of-cll-requiring-first-line-therapy
#2
REVIEW
Mischa Y L Vervoordeldonk, Paul J Hengeveld, Mark-David Levin, Anton W Langerak
The molecular landscape of chronic lymphocytic leukemia (CLL) has been extensively characterized, and various potent prognostic biomarkers were discovered. The genetic composition of the B-cell receptor (BCR) immunoglobulin (IG) was shown to be especially powerful for discerning indolent from aggressive disease at diagnosis. Classification based on the IG heavy chain variable gene (IGHV) somatic hypermutation status is routinely applied. Additionally, BCR IGH stereotypy has been implicated to improve risk stratification, through characterization of subsets with consistent clinical profiles...
April 15, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38608254/two-recurrent-types-of-igh-5-bcl2-breakpoints-representing-cytogenetic-ins-14-18-q32-q21q21-and-t-14-18-q32-q21-mediated-by-the-vdj-and-class-switch-recombination-processes-respectively
#3
JOURNAL ARTICLE
Fumiyo Maekawa, Masahiko Hayashida, Kayo Takeoka, Katsuhiro Fukutsuka, Miho Nakagawa, Takashi Akasaka, Shinichi Sakamoto, Shinji Sumiyoshi, Yoichiro Kobashi, Hitoshi Ohno
We describe two types of IGH :: BCL2 breakpoints involving the 5' region of BCL2 (5' BCL2 ). One was ins(14;18)(q32;q21q21) observed in 2 follicular lymphoma (FL) cases, in which IGH was cleaved at 3' of IGHD and 5' of IGHJ and BCL2 was cleaved at 5' BCL2 and downstream regions, and a 281- or 201-kilobase pair fragment containing the BCL2 protein-coding sequences was invertedly inserted into IGH . In another type observed in 2 FL and 2 chronic lymphocytic leukemia (CLL) cases, breakage and reunion occurred within the switch region associated with IGHM (Sµ) and 5' BCL2 , creating IGH Sµ::5' BCL2 fusion sequences on der(18)t(14;18)(q32;q21)...
April 12, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38608253/successful-treatment-with-cladribine-in-a-patient-with-rosai-dorfman-disease-complicated-by-severe-prolonged-marrow-aplasia
#4
JOURNAL ARTICLE
Tadeusz Robak, Marcin Braun, Anna Guminska, Elżbieta Iskierka-Jażdżewska, Paweł Robak
No abstract text is available yet for this article.
April 12, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38606813/correction
#5
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 12, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38600883/the-mechanism-of-action-pharmacological-characteristics-and-clinical-utility-of-the-amyloid-depleter-birtamimab-for-the-potential-treatment-of-al-amyloidosis
#6
REVIEW
Giovanni Palladini, Michaela Liedtke, Wagner Zago, Phil Dolan, Gene G Kinney, Morie A Gertz
Amyloid light chain (AL) amyloidosis is a progressive plasma cell disorder caused by amyloid deposition resulting in organ damage and failure. Current standard-of-care treatments target clonal plasma cells, the source of misfolded light chains (amyloid precursors), yet only half of patients with advanced disease survive ≥6 months. The amyloid depleter birtamimab is an investigational humanized monoclonal antibody that binds misfolded κ and λ light chains with high specificity and was designed to neutralize soluble toxic light chain aggregates and promote phagocytic clearance of deposited amyloid...
April 11, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38598516/safety-and-efficacy-of-parsaclisib-in-combination-with-rituximab-bendamustine%C3%A2-%C3%A2-rituximab-or-ibrutinib-in-patients-with-previously-treated-b-cell-lymphoma-analysis-of-a-phase-1-dose-finding-study-citadel%C3%A2-112
#7
JOURNAL ARTICLE
Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, Raul Cordoba, Monica Tani, Peter Langmuir, Erica Rappold, Teng Liu, Armando Lopez-Guillermo
Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The phase 1 CITADEL-112 (NCT03424122) study assessed safety and efficacy of parsaclisib in combination with investigator choice standard of care (SOC; rituximab [Treatment A], rituximab plus bendamustine [Treatment B], or ibrutinib [Treatment C]) in 50 patients with R/R B-cell lymphoma. The most common treatment-emergent adverse events included neutropenia (62...
April 10, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38597202/bruton-s-tyrosine-kinase-btk-inhibitors-for-the-treatment-of-primary-central-nervous-system-lymphoma-pcnsl-current-progress-and-latest-advances
#8
REVIEW
Lauren Schaff, Lakshmi Nayak, Christian Grommes
The incidence of primary central nervous system lymphoma (PCNSL) has steadily increased, particularly in elderly patients. Although highly responsive to first-line chemotherapy and radiotherapy, approximately 50% of patients relapse or become refractory within 1 year. Prognosis following relapse is dismal and no standard salvage therapy exists. Bruton's tyrosine kinase (BTK), a key regulator of the B-cell receptor (BCR) pathway, has emerged as a promising therapeutic target. The first BTK inhibitor ibrutinib has been evaluated in the relapsed/refractory PCNSL setting, with overall response rates of 51...
April 10, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38593054/the-prognostic-significance-of-genomic-complexity-in-patients-with-cll
#9
REVIEW
Ellinor Goergen, Othman Al-Sawaf
Chromosomal aberrations are a common feature of cancer and can fuel cancer progression and treatment resistance. In chronic lymphocytic leukemia (CLL), the presence of multiple chromosomal aberrations is commonly referred to as "genomic complexity" or "complex karyotype"- (CKT). In the context of chemo- and chemoimmunotherapy, genomic complexity is associated with poor response to treatment and short survival, while some targeted therapies are able to mitigate its adverse prognostic impact. This article reviews currently available data and literature on the role of genomic complexity in CLL...
April 9, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38587123/normal-and-malignant-cells-are-homogeneously-distributed-in-the-bone-marrow-of-children
#10
JOURNAL ARTICLE
Sharon Veenbergen, Romana Jugooa, Jeroen Te Marvelde, Andrica C H de Vries, Vincent H J van der Velden
No abstract text is available yet for this article.
April 8, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38581379/gammopathic-dermopathy-characterization-of-cutaneous-mgus
#11
JOURNAL ARTICLE
Emily R Gordon, Caroline Chen, Megan H Trager, Oluwaseyi Adeuyan, Brigit A Lapolla, Lauren M Fahmy, Celine M Schreidah, David A Wetter, Larisa J Geskin
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a clonal plasma cell disorder that is considered preneoplastic, asymptomatic, and only requiring observation. However, MGUS may result in cutaneous complications, which are poorly understood, causing treatment delays and patient suffering. We present 30 patients with cutaneous findings associated with MGUS, characterizing clinical presentations, isoforms, treatments, and outcomes. These included: MGUS-associated 'rashes' (pruritic eczematous rashes), reactive and mucin-depositional conditions (pyoderma gangrenosum, scleromyxedema), M-protein-related deposition disorders (POEMS syndrome, Waldenstrom macroglobulinemia), and cutaneous lymphomas...
April 6, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38567630/hospital-healthcare-resource-utilization-and-costs-for-chimeric-antigen-t-cell-therapy-and-autologous-hematopoietic-cell-transplant-in-patients-with-large-b-cell-lymphoma-in-the-united-states
#12
JOURNAL ARTICLE
Chendi Cui, Chaoling Feng, Ning Rosenthal, Sally W Wade, Laura Curry, Christine Fu, Gunjan L Shah
The efficacy of chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is well-established. This study, using the Premier PINC AI Healthcare Database, assessed hospital costs and healthcare resource utilization (HRU) between CAR T-cell therapy and autologous hematopoietic cell transplant (AHCT) for 733 LBCL patients from 01/01/2017-04/30/2021 (166 CAR T and 567 AHCT from 37 US hospital systems. CAR T-cell therapy had higher index costs but lower non-pharmacy costs, shorter hospital stays, lower ICU utilization than AHCT...
April 3, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38557299/successful-treatment-with-bortezomib-thalidomide-and-dexamethasone-in-plasma-cell-myeloma-post-bone-marrow-transplant
#13
JOURNAL ARTICLE
Yaqing Cao, Jingjing Shang, Yingying Zhai, Qingyuan Wang, Lingzhi Yan, Xiaolan Shi, Jing Wang, Ying Yao, Huifen Zhou, Aining Sun, Miao Miao, Chengcheng Fu, Song Jin
No abstract text is available yet for this article.
April 1, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38557285/phase-1-2-multicenter-trial-of-acalabrutinib-in-chinese-patients-with-relapsed-refractory-mantle-cell-lymphoma
#14
JOURNAL ARTICLE
Yuqin Song, Jianyong Li, Keshu Zhou, Xiaoyan Ke, Zhen Cai, Huilai Zhang, Tingting Yao, Zhen Xia, Yiqiu Wang, Peiqiong Lai, Xiaofeng Liu, Jun Zhu
Acalabrutinib studies have limited Asian participation. This phase 1/2 study (NCT03932331) assessed acalabrutinib in Chinese patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Primary endpoint was blinded independent central review (BICR)-assessed overall response rate (ORR). Overall, 34 patients were enrolled. Most patients were men (88%); median age was 63 years and 59% had ≥3 prior treatments. Median treatment duration was 14 months (range, 1-24). Any-grade adverse events (AEs) and grade ≥3 AEs occurred in 85...
April 1, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38538632/olutasidenib-in-post-venetoclax-patients-with-mutant-isocitrate-dehydrogenase-1-m-idh1-acute-myeloid-leukemia-aml
#15
JOURNAL ARTICLE
Jorge Cortes, Brian A Jonas, Gary Schiller, Alice Mims, Gail J Roboz, Andrew H Wei, Pau Montesinos, P Brent Ferrell, Karen Wl Yee, Pierre Fenaux, Anthony Schwarer, Justin M Watts
Olutasidenib, a potent, selective, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, is FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML). Here we report efficacy and safety of olutasidenib in 18 patients with m IDH1 AML who were relapsed (10), refractory (6) or had complete remission with incomplete hematologic recovery (CRi; 2) to a venetoclax combination. Of the 16 patients who were R/R, 4 (25%) achieved complete remission (CR), one (6.3%) achieved CR with partial hematologic recovery (CRh), and 7 (43...
March 27, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38535517/immunohistochemistry-based-detection-of-tp53-mutations-in-acute-myeloid-leukemia-a-promising-high-sensitivity-diagnostic-approach
#16
JOURNAL ARTICLE
Andrew Matthews, Elena Fenu, Sarah J Skuli, Jaryse C Harris, Catherine Lai
No abstract text is available yet for this article.
March 27, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38520720/significant-impact-of-antibiotic-exposure-on-gi-gvhd-nrm-and-grfs-following-allogeneic-hct-with-non-myeloablative-flu-tbi-conditioning
#17
JOURNAL ARTICLE
Lenneke F J van Groningen, Suzanne van Dorp, Manita E J Bremmers, Shahira Fazel, Mieke W H Roeven, Nicole M A Blijlevens, Walter J F M van der Velden
BACKGROUND: Acute gastro-intestinal graft- versus -host disease (GI-GVHD) and non-relapse mortality (NRM) after allogeneic HCT are closely related to loss of microbial diversity and intestinal dominance by single taxa resulting from the use of antibiotics, dietary changes, and mucosal barrier injury. There is a paucity of data on the impact of use of antibiotics in HCT after Flu-TBI-based non-myeloablative (NMA) conditioning where there is absence of mucositis and limited malnutrition...
March 23, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38517235/phase-ii-study-of-the-novel-antifolate-agent-pralatrexate-in-combination-with-the-histone-deacetylase-inhibitor-romidepsin-for-the-treatment-of-patients-with-mature-t-cell-lymphoma
#18
JOURNAL ARTICLE
Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, Seda Tolu, Brian Estrella, Ahmed Sawas, Jennifer K Lue, Mark M Francescone, Barbara Pro, Jennifer E Amengual
Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a multicenter Phase II study in patients with untreated or R/R mature T cell lymphomas (MTCL). Patients received pralatrexate 25 mg/m2 and romidepsin 12 mg/m2 every 2 weeks. Fourteen patients were evaluable for efficacy. Overall response rate was 35.7% with CR in 14.3% and disease control in 50%. The mDOR was 8.2 months, mPFS was 3...
March 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38516899/progressive-tp53-inactivation-in-an-aggressive-splenic-diffuse-red-pulp-small-b-cell-lymphoma
#19
JOURNAL ARTICLE
Maria-Myrsini Tzioni, Alexandra Clipson, Zi Chen, Francesco Cucco, Andrew Wotherspoon, Stefan Dojcinov, Ming-Qing Du
No abstract text is available yet for this article.
March 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38513148/predictive-value-of-early-molecular-response-to-tyrosine-kinase-inhibitors-in-pediatric-patients-with-chronic-myeloid-leukemia
#20
JOURNAL ARTICLE
Aya M Abdallah, Hanafy Hafez, Youssef Madney, Sonia Ahmed, Dina Yassin, Sherine Salem, Rodina Yousry, Hisham Abdel-Azim, Leslie Lehmann, Alaa Elhaddad
No abstract text is available yet for this article.
March 21, 2024: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.